• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Apheresis in the Treatment of Chronic Relapsing Polyneuropathy
【24h】

Apheresis in the Treatment of Chronic Relapsing Polyneuropathy

机译：血液成分治疗慢性复发性多发性神经病

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Office of Health Technology Assessment (OHTA) emphasizes three basic principles in its assessment activities: (1) broad and open participation both within and outside of the Federal government, (2) reliance on the expertise and research abilities of outside organizations and individuals, and (3) broad dissemination of assessment reports. This assessment focuses on apheresis in the treatment of chronic relapsing polyneuropathy. Despite a large and growing number of case reports and the small series of studies, a randomized clinical trial of apheresis has not been performed under any condition where it has been applied and the reported successes or failures must be categorized as being anedocotal. The theoretical basis for the use of apheresis in the treatment of chronic relapsing polyneuropathy appears attractive and its safety has been well documented. Convincing data of its efficacy must await the results from appropriate randomized clinical trials. Existing evidence from nonrandomized trials and case reports suggests that apheresis may improve the clinical course of some patients with chronic relapsing polyneuropathy and that this is a reasonable treatment for patients with severe or lifethreatening who have failed to respond to steroids and/or immunosuppression.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号